Christoph A Nienaber1, Natzi Sakalihasan2, Rachel E Clough3, Mohamed Aboukoura4, Enrico Mancuso5, James S M Yeh6, Jean-Olivier Defraigne2, Nick Cheshire5, Ulrich Peter Rosendahl5, Cesare Quarto5, John Pepper5. 1. Royal Brompton Hospital, London, United Kingdom; National Heart and Lung Institute, Imperial College London, London, United Kingdom. Electronic address: c.nienaber@rbht.nhs.uk. 2. Université Catholique de Liège, Liège, Belgium. 3. Aortic Centre, Hôpital Cardiologique, CHRU Lille, Lille, France; Division of Imaging Sciences and Biomedical Engineering, King's College London, London, United Kingdom. 4. Department of Cardiology, University Hospital Rostock, Rostock, Germany. 5. Royal Brompton Hospital, London, United Kingdom. 6. Royal Brompton Hospital, London, United Kingdom; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Abstract
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) has demonstrated encouraging results and is gaining increasing acceptance as a treatment option for aortic aneurysms and dissections. Yet, its role in managing proximal aortic pathologies is unknown-this is important because in proximal (Stanford type A) aortic dissections, 10% to 30% are not accepted for surgery and 30% to 50% are technically amenable for TEVAR. We describe our case series of type A aortic dissections treated by using TEVAR. METHODS: Between year 2009 and 2016, 12 patients with acute, subacute, or chronic type A aortic dissection with the proximal entry tear located between the coronaries and brachiocephalic artery were treated with TEVAR at 3 centers. Various stent-graft configurations were used to seal the proximal entry tear in the ascending aorta under rapid pacing. RESULTS: A total of 12 patients (9 male, 3 female), mean age 81 ± 7 years, EuroSCORE II 9.1 ± 4.5, underwent TEVAR for the treatment of type A aortic dissection. Procedural success was achieved in 11 of 12 patients (91.7%). There was 1 minor stroke and 1 intraprocedural death. No additional deaths were reported at 30 days. At 36 months, there were 4 further deaths (all from nonaortic causes). The mean survival of these 4 deceased was 23 months (range 15-36 months). Follow-up computed tomography demonstrated favorable aortic remodeling. CONCLUSIONS: TEVAR is feasible and reveals promising early results in selected patients with type A aortic dissection who are poor candidates for surgical repair. The current iteration of stent-graft technology, however, needs to be adapted to features specific to the ascending aorta.
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) has demonstrated encouraging results and is gaining increasing acceptance as a treatment option for aortic aneurysms and dissections. Yet, its role in managing proximal aortic pathologies is unknown-this is important because in proximal (Stanford type A) aortic dissections, 10% to 30% are not accepted for surgery and 30% to 50% are technically amenable for TEVAR. We describe our case series of type A aortic dissections treated by using TEVAR. METHODS: Between year 2009 and 2016, 12 patients with acute, subacute, or chronic type A aortic dissection with the proximal entry tear located between the coronaries and brachiocephalic artery were treated with TEVAR at 3 centers. Various stent-graft configurations were used to seal the proximal entry tear in the ascending aorta under rapid pacing. RESULTS: A total of 12 patients (9 male, 3 female), mean age 81 ± 7 years, EuroSCORE II 9.1 ± 4.5, underwent TEVAR for the treatment of type A aortic dissection. Procedural success was achieved in 11 of 12 patients (91.7%). There was 1 minor stroke and 1 intraprocedural death. No additional deaths were reported at 30 days. At 36 months, there were 4 further deaths (all from nonaortic causes). The mean survival of these 4 deceased was 23 months (range 15-36 months). Follow-up computed tomography demonstrated favorable aortic remodeling. CONCLUSIONS:TEVAR is feasible and reveals promising early results in selected patients with type A aortic dissection who are poor candidates for surgical repair. The current iteration of stent-graft technology, however, needs to be adapted to features specific to the ascending aorta.
Authors: Maximilian Kreibich; Bartosz Rylski; Stoyan Kondov; Julia Morlock; Johannes Scheumann; Fabian A Kari; Holger Schröfel; Matthias Siepe; Friedhelm Beyersdorf; Martin Czerny Journal: J Vis Surg Date: 2018-04-04
Authors: Alexander A Brescia; Himanshu J Patel; Donald S Likosky; Tessa M F Watt; Xiaoting Wu; Raymond J Strobel; Karen M Kim; Shinichi Fukuhara; Bo Yang; G Michael Deeb; Michael P Thompson Journal: Ann Thorac Surg Date: 2019-08-07 Impact factor: 4.330
Authors: Yunus Ahmed; Ignas B Houben; C Alberto Figueroa; Nicholas S Burris; David M Williams; Frans L Moll; Himanshu J Patel; Joost A van Herwaarden Journal: J Card Surg Date: 2020-11-10 Impact factor: 1.620